期刊文献+

血液透析和腹膜透析患者心血管疾病危险因素比较 被引量:1

下载PDF
导出
摘要 慢性肾功能疾病患者发生心血管事件较健康人会增加25%~65%,而透析患者则会呈20~40倍增高[1],这可能与几个因素有关,如贫血、电解质代谢紊乱、高血压、胰岛素血症、高血脂、氧化应激压力和炎症[2]. 心血管疾病是透析患者的重要死因[3],高达40%~50%.一些研究显示腹膜透析者更容易出现高脂血症和高胰岛素血症[4]. 腹膜透析液为含糖透析,腹膜透析患者每日吸收腹膜透析液中的葡萄糖,因此,更容易引起血糖升高,增加控制血糖的难度,血糖升高可引起热量过剩,并导致肥胖和高脂血症,腹膜透析患者脂质紊乱、高胰岛素血症明显高于血液透析患者,在肾置换术治疗中也更容易出现炎症和氧化应激,因而相应地同型半胱氨酸(又称高半胱氨酸,homocysteine,Hcy)、体质量指数(body mass index, BMI)、C反应蛋白(CR )和营养不良增加了心血管发生事件危险性. 胰岛素抵抗和高胰岛素血症更容易出现在终末期肾脏疾病中. 本研究旨在比较腹膜透析患者心血管危险因素与炎症、动脉粥样硬化和代谢综合症之间的相关性.
作者 雷立军
出处 《实用医技杂志》 2016年第12期1320-1322,共3页 Journal of Practical Medical Techniques
  • 相关文献

参考文献3

二级参考文献15

  • 1The Inter national Quotidian Dialysis Registry: annunal re- port 2005 [ R ]. Hemodial Int, 2005, 9 (3) : 203-209.
  • 2Weiner DE, Tighiouart H, Amin MG, et al. Chronic kid- ney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies[J]. Am Soc Nephrol, 2005, 15(5) : 1 307-315.
  • 3Agarwal R, Nissenson AR, Battle D, et al. Prevalence, treatment, and control of hypertension in chronic hemodial- ysis patients in theUnited States [ J ]. Am J Med, 2003, 115(4) : 291-297.
  • 4LondonGM, PannierB, GuerinAP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study [ J ]. J Am Soc Nephrol, 2001, 12(12): 2 759-767.
  • 5Heerspink H J, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mor- tality in patients on dialysis: a systematic review andmeta- analysis of randomised controlled trials [ J ]. Lancet, 2009, 373(9 668) : 1 009-015.
  • 6Inrig JK, Patel UD, Gillespie BS, et al. Relationship be- tween interdialytic weight gain and blood pressure among prevalent hemodialysis patients [ J ]. Am J Kidney Dis, 2007, 50(1) : 108-118.
  • 7Attman PO, Samuelsson O, Alaupovic P. Lipoprotein me- tabolism in renal failure [ J ]. Am J Kidney Dis, 1993, 21 (6) : 573-592.
  • 8Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/ CRP evaluation (PRINCE): a randomized trial and cohort study[J]. JAMA, 2001,286(1) : 64-70.
  • 9US Renal Data System: USRDS 1999 Annual Data Report [ D]. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 1999.
  • 10Masterson TM. Safety and efficacy of simvastatin in pa- tients undergoing chronic renal dialysis: are we ready to treat hypercholesterolemia[ J ]. Am J Kidney Dis, 2002, 39(2) : 419-421.

共引文献48

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部